What is Immuneering's latest dividend and current dividend yield?

What were the key takeaways from Immuneering's earnings call?

What is the market's earnings forecast for Immuneering next quarter?

What were the key takeaways from Immuneering’s earnings call?

What guidance did Immuneering's management provide for the next earnings period?

What is Immuneering's gross profit margin?

Did Immuneering beat or miss consensus estimates last quarter?

What does Immuneering do and what are its main business segments?

- **Breakthrough Pancreatic Cancer Data**: 86% overall survival at nine months vs. 47% standard care, with complete responses in FOLFIRINOX combo arm.
- **$227M Cash Runway**: 2029 funding secured for phase 3 trial and lung cancer collaborations.
- **Unique Mechanism**: Deep cyclic MEK inhibition blocks resistance, no MAPK pathway mutations detected.
- **Upcoming Trials**: Phase 3 pancreatic cancer start mid-2026; Libtayo lung trial H2 2026; Lilly KRAS G12C combo pending.

**【CEO Opening Remarks】**
- Presented two case studies from the phase 2A trial of Tevid MetNib in combination with FOLFIRINOX, highlighting complete responses and durable tumor shrinkage in first-line pancreatic cancer patients.
- Emphasized Tevid MetNib's tolerability, with patients reporting improved quality of life and no significant adverse events beyond grade 3 in more than 10% of patients.
- Announced a $225 million capital raise, extending the cash runway into 2029, and shared plans for a pivotal phase 3 trial in first-line pancreatic cancer patients with gemcitabine nab-paclitaxel.

**【CFO Financial Commentary】**
- Cash and cash equivalents as of September 30, 2025: $227.6 million, up from $36.1 million at year-end 2024.
- Secured $25 million strategic investment from Sanofi and a $175 million underwritten offering, supporting clinical development and operations through 2029.

**【Q&A Highlights】**
- **Competitive Position**: CEO stated Tevid MetNib's 86% overall survival at nine months vs. 47% for standard care makes it the leader in first-line pancreatic cancer. Tolerability and durability differentiate it from RAS inhibitors.
- **Future Trials**: Phase 3 trial in first-line pancreatic cancer expected to begin mid-2026. Trials with Regeneron's Libtayo (anti-PD-1) in lung cancer to start H2 2026; Eli Lilly collaboration for KRAS G12C inhibitor combo to follow.
- **Cash Allocation**: Funded for phase 3 trial, lung cancer studies, and preclinical pipeline expansion.
- **Adjuvant Setting**: Exploring potential for Tevid MetNib in adjuvant pancreatic cancer post-surgery, though first priority remains first-line setting.
- **Mechanism of Action**: Deep cyclic inhibition at MEK blocks resistance mechanisms, with no acquired MAPK pathway mutations observed in early data.

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

IMRX

IMRX fundamentals

You can ask Aime